PREVALENCE OF ALL ERGY IN RELATION TO NUTRITIONAL ALLERGEN CHALLENGE. GASTROINTESTINAL AND RESPIRATORY TRACT INFECTIONS (RTI) IN AT RISK INFANTS Claudia C. Vassella, Ursula Bühlmann, Marianne Bättig, Eduard Gugler, Beda M. Stadler and Richard Kraemer. Department of Paediatrics and Institute of Clinical Immunology, University of Berne, Inselspital, CH-3010 Berne, Switzerland

Aim: Development of allergy was studied in relation to nutritional allergen challenge and infectious diseases during the first 16 months of life.

Methods: 240 infants were allocated either to breast-milk feeding during first 5 months, followed by a hypoallergenic diet (BM), or hypoallergenic whey formula feeding (Nidina HA, Nestlé: HA). Results: In a high risk group of infants (positive family history and cord blood IgE > 0.5 KU/L) prevalence of atopic disease was similarly frequent in both nutritional groups (BM 12 %, HA 11 % at age 4 months; 32 %, 39 % at age 16 months resp.). While upper RTI equally frequent occurred in both nutritional groups, the HA group showed a significantly higher prevalence of lower RTI (BM 12 %; HA 36 %; p < 0.05), associated with a more frequent development of respiratory allergy (29 % with lower RTI; 2 % without lower RTI; p < 0.005) Other atopic diseases (skin and gastrointestinal symptoms) occurred in 19 % of infants with lower RTI and 22 % without lower RTI (n.s.). Prevalence of atopic disease was also significantly different in relation to gastrointestinal infections (41 % with vs. 25 % without), although gastrointestinal intolerance was similar in both groups (38 % vs. 40 %).

Similar and out groups (or no var). Conclusion: While there was a similar allergy prevalence in Nidina HA fed and breast-milk fed infants at risk, a particular group of infants exposed to gastrointestinal or lower RT infections showed a higher allergy prevalence in association with Nidina HA feeding and should therefore favorably be nourished by breast-milk.

## • 236

ANTENATAL GLUCOCORTICOID ADMINISTRATION IN A NATIONWIDE COHORT OF VERY PRETERM AND VERY LOW BIRTHWEIGHT INFANTS: FOLLOW-UP AT 5 YEARS OF AGE Sylvia Veen', Anneke M. Schreuder', Martina H. Ens-Dokkum', Robert A.

Verwey', Ronald Brand<sup>2</sup>, S. Pauline Verloove-Vanhorick<sup>1</sup>, Jan H. Ruys<sup>1</sup>, <sup>1</sup>Dept of Pediatrics and <sup>2</sup>Medical Statistics, Univ. Hosp. Leiden, The Netherlands.

The relationship between antenatally administered glucocorticoids and overall outcome at 5 years of age, applying stepwise logistic regression analyses with 14 confounding factors, was studied. Data were collected on 1338 liveborn infants (gestational age < 32 wks and/or birthweight <1500 g) born in 1983 in the Netherlands. Data were analyzed in a subset of 671 infants (gest. age  $\geq$  26 and <32 wks) of whom 642 had been assessed at 5 years of age (loss to follow-up 4.3%). Overall outcome expressed as impairment, disability or handicap (WHO, 1980) was based on: congenital malformation, neuromotor function, mental development, hearing, visual function, language and speech development, musculoskeletal system, respiratory tract. There was no higher risk of impairment at 5 years of age in children of treated mothers versus non-treated mothers. With disability or handicap as outcome variables there was a significant interaction of glucocorticoid treatment and tocolysis. In the presence of tocolysis (>24 hours) there was no higher risk on disability or handicap at 5 years of age. In 13 children whose mothers received no tocolysis or only <24 hours, the antenatal administration of glucocorticoids was associated with a significantly higher risk on disability or handicap, probably a result of confounding by indication of the treatment.

## • 237

LONG-TERM NEUROLOGICAL AND COGNITIVE OUTCOME OF CHILDREN WHO WERE

Van der Veer E<sup>1</sup>, Olthof E<sup>1</sup>, De Vries TW<sup>3</sup>, Heijmans HSA<sup>2</sup>, Smrkovsky M<sup>2</sup>, Geven-Boere LM<sup>4</sup>, & Touwen BCL<sup>2</sup>, Univ. Hospital<sup>1</sup> & State Univ.<sup>2</sup> Groningen; Med. Center Leeuwar-den<sup>3</sup>; Dutch Fed. Thrombosis Centers<sup>4</sup>, s'Gravenhage, the Netherlands. Perinatal studies have shown that intra-uterine exposure to coumarins may influence the development of bone and neural tissues. To study the late effects of prenatal exposure to coumarins, physical, neurological, and mental development were assessed. In a pilot study 21 index (I) children and 17 controls (C) were examined at the age 8-10 years. Results:

number of	IQ-score		Reading		Neur.exam (n; NOS)		Paed.exam (n)		
children	1	С	I	C	1	с	1	<u> </u>	
no participation	-	2	-	2	1				
high	2	1	2	-	18 (55-62)	14 (54-61)	14	11	normal
average	15	14	13	14	2 (42-48)	3 (55-58)	6	6	minor
low	3	-	4	1	1 (19)		1	-	abnormal
upphia to cooro	1		2	I					

unable to score 1 2 mean score: 99 103 4.7 5.1 Conclusions: No statistical significant differ-ences were found between the index and control group in this small study. Nevertheless, an indication seemed to be present for a possible effect of prenatal exposure to coumarins. Five children showed minor neurological dysfunction (MMD); the two children with the more serious variant (NOS = neurological optimality score 42-48) had both been exposed to coumarins. The distribution of the IQ-scores corresponded with the distribution of the IQ-scores corresponded with the distribution. bution of the scores in the Dutch standardization sample. There were 3 children with an IQ < 80. All three had been exposed to oral anticoagulants during pregnancy in the 2nd and 3rd (n = 2), or in the 3rd trimester only. One child with severe abnormalities, namely hypoplasis of both optic nerves, cerebral palsy and retardation, had been exposed during the 2nd and 3rd trimester of pregnancy. Paediatric exam directly post partum revealed no abnormalities. In view of these results a large follow-up study is required.

ANTIOXIDANT ADMINISTRATION TO THE MOTHER PREVENTS OXIDATIVE STRESS ASSOCIATED WITH BIRTH IN THE NEONATAL RAT.NVento',FGarcia-Sala,JCatalá,JViña'',JSastre,MAsensi. H.Casa Salud'& Dpto de Fisiologia'',Univ Valencia(Spain). With birth circulatory and respiratory changes ensug With birth circulatory and respiratory changes ensue leading to fetal oxidative stress evidenced by changes in the glutathione status.Pregnant rats receiving NAC during gestation were sacrificed at 21±16.Fetuses delivered by c-section and immediately sacrificed and newborns at 24h age.Livers were processed(1) and GSH and GSSG determined. Results were as follows: Fetuses Neonates Pregnant rats

	Fetuses		Neona	tes	Pregnant	rats	
	Controls	+NAC	Controls	+NAC	Controls	+NAC	
GSH	3.1±.4 3	.9±.2**	3.4±.7 3	.7±.3	5.7±.9	5.7±1.2 <sup>&amp;&amp;</sup>	
(µmol	/g)(6)	(5)	(10)	(5)	(9)	(4)	
GSSG	1.0±.2	5.0±2**	' 12±5##	9±4	30±10 <sup>&amp;</sup>	52±3&&	
(nmol	/g)(5)	(5)	(11)	(5)	(4)	(4)	
GSH/G	SSG 3100	981	283	471	172	112	
**p<0.01, *p<0.05:NAC/Controls; ##p<0.01, #p<0.5:Neonates/							
Fetuses; &&p<0.01, &p<0.05: Pregnant rats/Neonates.							
We conclude that oxidative stress associated with birth							
in rat fetuses might be partially prevented by NAC given							
to the mother during gestation.							
(1) V	iña J et	al; Biod	chem J 17	0; 627	-630 (1978	)	

## • 239

ONSET MORTALITY IN INSULIN DEPENDENT DIABETES MELLITUS S.P. Verloove-Vanhorick, R.A. Hirasing, M. Reeser, F. Böhm, Y.B. Oei, G.J. Vaandrager. Department of Public Health (Child Health), TNO-Prevention and Public Health, Leiden

From data of the second nationwide incidence study in 1988-1990 on Insulin Dependent Diabetes Mellitus (IDDM) in children aged 0-19 years and of the population based registe of mortality data the onset mortality in various age groups was calculated (table). Compared to the previous nationwide study in 1978-1980, the incidence of IDDM had increased, especially in the age group 4-19 years, but the onset mortality risk was significantly lower, although not yet zero. It is important to continue to monitor the mortality of IDDM cases for trends and to get clues for prevention of such deaths.

1978-1980				1988-1990			
age group	deaths	new IDDM patients	mortality risk % (95% Ct)	deaths	new IDDM patients	mortality risk % (95% CI)	
0-4	3	183	1.64(0.33-4.79)	1	178	0.56(0.01-3.13)	
5-9	1	363	0.28(0.01-1.53)	-	331		
10-14	2	527	0.38(0.05-1.37)	1	496	0.20(0.01-1.12)	
15-19	5	391	1.28(0.42-2.98)	1	522	0.19(0.01-1.07)	
0-19	11	1464	0.75(0.38-1.34)	3	1527	0.20(0.04-0.57)	

## • 240

CALCIUM METABOLISM IN CHILDREN WITH PRECOCIOUS PUBERTY TREATED WITH GnRH AGONIST

Alberto Verrotti, Mariano Magri, Francesco Chiarelli, Guido Morgese Department of Pediatrics, University of Chieti, Italy

In order to evaluate the effects of slow-release gonadotropin-releasing hormone analogues on calcium metabolism, we studied 10 (7 female, 3 male) children with central precocious puberty, treated with GnRH agonist D-Trp6-GnRH (Decapeptyl, Ipsen), their mean  $\pm$  SD age was 5.5  $\pm$  3.1 years. The patients were studied before the beginning (f0) and after 6 months of the studied before the beginning (f0) and after 6 months of the studied before the beginning (f0) and after 6 months of the studied before the beginning (f0) and after 6 months of the studied before the beginning (f0) and after 6 months of the studied before the beginning (f0) and for the studied b treatment (t1). Twelve sex and age-matched healthy children were also studied. We evaluated Bone Mineral Content (BMC) and serum levels of calcium, phosphorus, magnesium, PTH (M 44-68), CT, 25-OH-vitamin D

	tO	tl	Controls
BMC (g/cm2)	0.51 ± 0.12**	0.42 ± 0.11*	0.39 <u>+</u> 009
Ca (mg/dl)	9.3 <u>+</u> 1.1	$9.2 \pm 1.0$	9.2 <u>+</u> 0.9
P (mg/dl)	3.8 ± 1.1	3.9 <u>+</u> 1.0	3.9 <u>+</u> 1.1
Mg (mg/dl)	2.2 ± 0.4	2.1 <u>+</u> 0.6	$2.2 \pm 0.6$
25-OH-D (ng/ml)	23.11 <u>+</u> 4.87	22.67 ± 4.64	23.5 ± 5.80
PTH (ng/dl)	6.02 <u>+</u> 5.11	5.33 ± 4.25	6.23 ± 5.38
CT (pg/ml)	37.41 ± 16.1	35.99 ± 14.79	36.75 ± 15.34
0 vs controls: * p< 0.0	01, ** p< 0.001		

At 10, the 24 hour exerction of calcium, phosphorus and magnesium were similar to control group and did not changed at t1. Our study shows that children with precocious puberty have an increased BMC and that gonadotropin-releasing hormone analogues modify bone density. with a consequent its reduction; this reduction seems not related to calcium metabolism